Novel Therapy May Boost Efficacy of Chemotherapy Backbone in mCRC

Rachel Narozniak, MA
Published: Monday, Nov 18, 2019
Howard S. Hochster, MD, a Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School, Seattle Cancer Care Alliance

Howard S. Hochster, MD

Can the novel agent arfolitixorin supplant leucovorin calcium, a widely used component of combination regimens for patients with metastatic colorectal cancer (mCRC)? Investigators are seeking to answer that question in a phase III trial now underway.

Investigators are seeking to recruit at least 440 participants at sites in the United States, Canada, Western Europe, and Japan. The primary end point of the parallel-group study is objective response rate (ORR). Secondary end points are progression-free survival (PFS) and duration of response.

Figure. ARFOX With Bevacizumab in Advanced CRC

Figure. ARFOX With Bevacizumab in Advanced CRC
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication